{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T18:26:34Z","timestamp":1772303194531,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatocellular carcinoma (HCC) with lung metastases is associated with a poor prognosis due to limited effective treatment options. Emerging evidence suggests that combining locoregional therapy, multi-kinase inhibitors (MKIs), and immune checkpoint inhibitors (ICIs) offers promising results for advanced HCC. However, the efficacy of innovative combinations of MKIs and ICIs remains inconclusive. Herein, we present a case of a patient with massive HCC and lung metastases, complicated with decompensated hepatitis B cirrhosis, who achieved complete remission (CR) lasting for 10 months following treatment with lenvatinib (an MKI), camrelizumab (a PD-1 inhibitor), and locoregional therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>A 58-year-old male patient with decompensated hepatitis B-induced liver cirrhosis and advanced HCC with lung metastases underwent drug-eluting bead transarterial chemoembolization (DEB-TACE) therapy. Initially, he received apatinib in combination with camrelizumab; however, due to intolerance to apatinib\u2019s side effects, the regimen was adjusted to lenvatinib and camrelizumab. After three DEB-TACE sessions, 14 weeks of lenvatinib, and a 5-month course of camrelizumab, the patient achieved CR, with no tumor recurrence observed over 10 months of follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The combination of DEB-TACE, lenvatinib, and camrelizumab demonstrated efficacy in a patient with advanced HCC and lung metastases. These findings suggest that integrating MKIs and ICIs may represent a potential treatment approach for select advanced HCC cases, warranting further validation in larger studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1549675","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:22:04Z","timestamp":1750396924000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB\u2212TACE combined with lenvatinib and camrelizumab"],"prefix":"10.3389","volume":"16","author":[{"given":"Baiguo","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongsong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiling","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.molimm.2023.08.006","article-title":"Tumor-derived exosomes promote macrophages M2 polarization through miR-1-3p and regulate the progression of liver cancer","volume":"162","author":"Gu","year":"2023","journal-title":"Mol Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25960","article-title":"Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors","volume":"117","author":"Uchino","year":"2011","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06917.x","article-title":"Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases","volume":"27","author":"Jung","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2014.259","article-title":"Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis","volume":"2","author":"Aino","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7150\/jca.19056","article-title":"Pattern of distant extrahepatic metastases in primary liver cancer: a SEER based study","volume":"8","author":"Wu","year":"2017","journal-title":"J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s192896","article-title":"Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung metastasis: a population-based study","volume":"11","author":"Wu","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-017-1779-y","article-title":"Aggressive intrahepatic therapies for synchronous hepatocellular carcinoma with pulmonary metastasis","volume":"20","author":"Hu","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000523849","article-title":"Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with unresectable, advanced hepatocellular carcinoma: a real-world, multicenter, retrospective study","volume":"11","author":"Xia","year":"2022","journal-title":"Liver Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00808","article-title":"Phase ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/14737140.2022.2039123","article-title":"Lenvatinib dose, efficacy, and safety in the treatment of multiple Malignancies","volume":"22","author":"Motzer","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00001","article-title":"Management and treatment of hepatocellular carcinoma with immunotherapy: a review of current and future options","volume":"8","author":"Ghavimi","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)30427-1","article-title":"Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"394","author":"Zhou","year":"2017","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2019.01.020","article-title":"Corrigendum to EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Raoul","year":"2018","journal-title":"J Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-09-0280","article-title":"Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts","volume":"8","author":"Roland","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)08649-x","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2023-0001","article-title":"Comparison of CalliSpheres(\u00ae) microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial","volume":"57","author":"Shi","year":"2023","journal-title":"Radiol Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/hepr.12450","article-title":"Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma","volume":"45","author":"Xie","year":"2015","journal-title":"Hepatol Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12439","article-title":"Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma","volume":"29","author":"Huang","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.10224","article-title":"Renal diffusion and BOLD MRI in experimental diabetic nephropathy. Blood oxygen level-dependent","volume":"17","author":"Ries","year":"2003","journal-title":"J Magn Reson Imaging"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.94.12.3271","article-title":"Noninvasive evaluation of intrarenal oxygenation with BOLD MRI","volume":"94","author":"Prasad","year":"1996","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01116-x","article-title":"A review in hepatocellular carcinoma","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002305","article-title":"Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma","volume":"9","author":"Deng","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S332420","article-title":"Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study","volume":"8","author":"Wu","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S304820","article-title":"Lenvatinib plus camrelizumab versus lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma: a short-term prognostic study","volume":"13","author":"Wei","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","article-title":"Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/agt2.552","article-title":"Rhein-based Pickering emulsion for hepatocellular carcinoma: Shaping the metabolic signaling and immunoactivation in transarterial chemoembolization","volume":"5","author":"Liang","year":"2024","journal-title":"Aggregate"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1549675\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:22:05Z","timestamp":1750396925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1549675\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2025.1549675"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1549675","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"article-number":"1549675"}}